TRPC6 channel blocker as potential therapeutics for pulmonal and renal diseases
The invention comprises diterpene derivatives for the treatment of pulmonary hypertension in conjunction with respiratory disorders, especially asthma and COPD. The pharmacological effect is mediated by selective block of TRPC6, a member of the subfamily of canonical transient receptor potential channels.
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Microscopic basis of a new form of quantum magnetism
Not all magnets are the same. When we think of magnetism, we often think of magnets that stick to a refrigerator’s door. For these types of magnets, the electronic interactions…
An epigenome editing toolkit to dissect the mechanisms of gene regulation
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology, which unlocks the ability to precisely program chromatin modifications. Understanding how…
NASA selects UF mission to better track the Earth’s water and ice
NASA has selected a team of University of Florida aerospace engineers to pursue a groundbreaking $12 million mission aimed at improving the way we track changes in Earth’s structures, such…
